< 1 minute read
Mar. 14, 2023

Emraclidine: a Selective Positive Allosteric Modulator of the Cholinergic M4 Muscarinic Receptor

Cerevel/Pfizer M4 positive allosteric modulator

oral, QD M4 PAM Ph. II for schizophrenia discovery not disclosed emraclidine (CVL-231) Cerevel Therapeutics, Cambridge, MA; Pfizer, New York, NY


Molecules of the Month

MOTY Nominees

Molecule of the Year